Prognostic significance of baseline C-reactive protein/albumin ratio for long-term outcomes in advanced gastric cancer under immunochemotherapy

Table 5 Comparison of adverse events stratified by C-reactive protein to albumin ratio (< 0.21 vs ≥ 0.21) in advanced gastric cancer, n (%)

Variables	Total (n = 200)	High (n = 80)	Low (n = 120)	χ2 value	P value
Leukopenia	79 (39.50)	34 (42.50)	45 (37.50)	0.50	0.479
Anemia	83 (41.50)	32 (40.00)	51 (42.50)	0.12	0.725
Neutropenia	80 (40.00)	32 (40.00)	48 (40.00)	0.00	1.000
Thrombocytopenia	72 (36.00)	33 (41.25)	39 (32.50)	1.60	0.207
Nausea	61 (30.50)	26 (32.50)	35 (29.17)	0.25	0.616
Pyrexia	51 (25.50)	23 (28.75)	28 (23.33)	0.74	0.389
Elevated ALT	37 (18.50)	18 (22.50)	19 (15.83)	1.41	0.234
Elevated AST	41 (20.50)	17 (21.25)	24 (20.00)	0.05	0.830
Hypothyroidism	37 (18.50)	15 (18.75)	22 (18.33)	0.01	0.941
Diarrhea	39 (19.50)	19 (23.75)	20 (16.67)	1.53	0.215
Hypertension	26 (13.00)	13 (16.25)	13 (10.83)	1.25	0.264
Pneumonitis	22 (11.00)	10 (12.50)	12 (10.00)	0.31	0.580
Proteinuria	23 (11.50)	10 (12.50)	13 (10.83)	0.13	0.717
Hyperbilirubinemi	18 (9.00)	7 (8.75)	11 (9.17)	0.01	0.920
Fatigue	26 (13.00)	12 (15.00)	14 (11.67)	0.47	0.492
≥ 3 grades: Thrombocytopenia	35 (17.50)	16 (20.00)	19 (15.83)	0.58	0.447
≥ 3 grades: Neutropenia	25 (12.50)	12 (15.00)	13 (10.83)	0.76	0.383
≥ 3 grades: Leukopenia	20 (10.00)	7 (8.75)	13 (10.83)	0.23	0.630
≥ 3 grades: Anemia	15 (7.50)	5 (6.25)	10 (8.33)	0.30	0.584
≥ 3 grades: Diarrhea	6 (3.00)	3 (3.75)	3 (2.50)	0.01	0.933
≥ 3 grades: Nausea	9 (4.50)	4 (5.00)	5 (4.17)	0.00	1.000
≥ 3 grades: Elevated ALT	7 (3.50)	3 (3.75)	4 (3.33)	0.00	1.000
≥ 3 grades: Elevated AST	6 (3.00)	2 (2.50)	4 (3.33)	0.00	1.000
≥ 3 grades: Hypothyroidism	5 (2.50)	2 (2.50)	3 (2.50)	0.00	1.000
≥ 3 grades: Hypertension	4 (2.00)	2 (2.50)	2 (1.67)	0.00	1.000
≥ 3 grades: Pneumonitis	3 (1.50)	2 (2.50)	1 (0.83)	0.13	0.722
≥ 3 grades: Hyperbilirubinemia	4 (2.00)	2 (2.50)	2 (1.67)	0.00	1.000

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.